// App-Quantinova.ai

: Cytomegalovirus and Epstein-Barr Virus Infection during Daratumumab Treatment in Patients with Multiple Myeloma

Researchers

Presenter

  • Shuchan Li

Principal Investigators

  • Xiaoyan Han

  • Enfan Zhang

  • He Huang

  • Zhen Cai

Medical Centers

  • The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

  • Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China

  • Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

  • Department of Hematology, The First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China

  • Institute of Hematology, Zhejiang University, Hangzhou, China

  • Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

  • Liangzhu Laboratory, Zhejiang University Medical Center, West Wenyi Road, Hangzhou , China, Hangzhou, China

  • The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Cytomegalovirus infection

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved